The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- AZ’s Olaparib Filed for Breast Cancer in 2nd Submission
October 24, 2017
- Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030
October 24, 2017
- Harvoni Hits 96% SVR12 Rate in Japanese Genotype 2 Hep C Patients
October 23, 2017
- Romosozumab Shows Consistent Efficacy, Safety in Japanese Osteoporosis Patients: Amgen Astellas
October 23, 2017
- Astellas Inks Collaboration with Universal Cells to Develop Novel Cell Therapy
October 23, 2017
- Seebri Neohaler Now Available in the US: Sunovion
October 23, 2017
- Lonsurf Earns Priority Status in Canada: Taiho
October 23, 2017
- Topical Sirolimus, 1st Sakigake-Designated Drug, Filed in Japan: Nobelpharma
October 23, 2017
- Kaketsuken Mum on Reported Biz Transfer to Kumamoto Consortium-Led Firm
October 20, 2017
- Mitsubishi Tanabe’s NeuroDerm Acquisition Completed
October 20, 2017
- LEO Pharma Japan to Set Up Stand-Alone Sales Force in 5 Years, Eyes 100 Reps
October 20, 2017
- Takeda’s Entrepreneurship Scheme Attracts 30 Proposals
October 20, 2017
- Boehringer, Nagoya City Univ. Collaborate on Diabetic Retinopathy Research
October 19, 2017
- Astellas, US Nonprofit Join Forces to Discover TB Drugs
October 19, 2017
- Takeda, HemoShear Link Up in Drug Discovery for Liver Diseases
October 19, 2017
- Daiichi Sankyo, Saitama Medical Univ. Launch AMED-Funded Research on FOP Therapy
October 19, 2017
- Daiichi Sankyo in Exosome Research Deal with NCC, Devices Makers
October 19, 2017
- Kyowa Kirin Eyes US Resubmission for Nouriast Next Year
October 18, 2017
- Bayer Files Long-Acting Hemophilia A Treatment in Japan
October 18, 2017
- Otsuka Seeks Japan Approval of Alcohol Dependence Med Nalmefene
October 18, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…